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Abstract
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Stress has been reported to activate the locus coeruleus (LC)–noradrenergic system. In the present
study, corticosterone (CORT) was orally administrated to rats for 21 days to mimic stress status.
In situ hybridization measurements showed that CORT ingestion significantly increased mRNA
levels of norepinephrine transporter (NET) and dopamine β-hydroxylase (DBH) in the LC region.
Immunofluorescence staining and western blotting revealed that CORT treatment also increased
protein levels of NET and DBH in the LC, as well as NET protein levels in the hippocampus, the
frontal cortex and the amygdala. However, CORT-induced increase of DBH protein levels only
appeared in the hippocampus and the amygdala. Elevated NET and DBH expression in most of
these areas (except for NET protein levels in the LC) was abolished by simultaneous treatment
with combination of corticosteroid receptor antagonist mifepristone and spironolactone (s.c. for 21
days). Also, treatment with mifepristone alone prevented CORT-induced increases of NET
expression and DBH protein levels in the LC. In addition, behavioral tasks showed that CORT
ingestion facilitated escape in avoidance trials using an elevated T-maze, but interestingly, there
was no significant effect on the escape trial. Corticosteroid receptor antagonists failed to
counteract this response in CORT-treated rats. In the open-field task, CORT treatment resulted in
less activity in a defined central zone compared to controls and corticosteroid receptor antagonist
treatment alleviated this increase. In conclusion, the present study demonstrates that chronic
exposure to CORT results in a phenotype that mimics stress-induced alteration of noradrenergic
phenotypes, but the effects on behavior are task-dependent. As the sucrose consumption test
strongly suggests CORT ingestion-induced depression-like behavior, further elucidation of
underlying mechanisms may improve our understanding of the correlation between stress and the
development of depression.
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It is well known that both chronic stress and dysfunctional noradrenergic systems are
causatively involved in the pathophysiology of major depressive disorder (MDD). Animal
studies have revealed that prolonged exposure to various stressors resulted in the
motivational, neuroendocrine, anhedonic, and behavioral characteristics observed in human
depression (Brady 1994, Sapolsky 1996). On the other hand, deficiencies of noradrenergic
transmission have been thought to be one factor for the etiology of depression (Schatzberg et
al. 1995, Charney 1998). Furthermore, many lines of evidences have revealed that the
interaction between chronic stress and the noradrenergic system may contribute to the
development of depression. For example, animal studies have shown that the brain
noradrenergic system is rapidly activated by different stressors (Korf et al. 1973, Anisman et
al. 1979, Abercrombie et al. 1987, Ritter et al. 1998), which results in an increase of
norepinephrine (NE) release from noradrenergic terminals (Pacak et al. 1995, Smagin et al.
1997, Rosario et al. 1999), and this can lead to an overall reduction of brain NE levels
(Weiss et al. 1980, Carboni et al. 2010). Nevertheless, the underlying mechanisms are far
from being fully understood. Exploring the molecular links of the interaction between
chronic stress and alteration of the noradrenergic system is worthwhile for elucidating the
biological basis of depression and identifying new treatments.
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Stress triggers multiple biological reactions in different organisms and systems including the
release of several stress-related hormones. Among them, as the final effector of the
hypothalamus-pituitary-adrenal (HPA) axis, glucocorticoids have been implicated in most of
the reported stress-induced physiological changes in brains (McEwen, 1999) through their
ubiquitously distributed intracellular receptors (Bamberger et al. 1996). It has been
suggested that prolonged stress-induced hypersecretion of glucocorticoids may form part of
the intrinsic mechanism underlying the development of depression (Carrasco and Van de
Kar, 2003). Thus, understanding glucocorticoid-induced modulation on neural systems may
further clarify the relationship between stress and depression.

NIH-PA Author Manuscript

Generally, the central noradrenergic system is one of the targets modulated by
glucocorticoids (Dallman et al. 2006). The noradrenergic system acts as an arousal and
alerting system to enhance organismic function and behaviors. Therefore, interaction
between glucocorticoid and noradrenergic systems may play an important integrative
function in coping and adaptation to stress. Both the NE transporter (NET) and dopamine βhydroxylase (DBH, EC 1.14.17.1) are the important endophenotype of the noradrenergic
system. NET has the primary function for reuptake of NE from presynaptic terminals of
noradrenergic nerves, by which NE transmission is inactivated at the synapse (Barker et al.
1995). DBH is an enzyme that catalyzes the oxidation of dopamine to NE (Friedman et al.
1965). Both NET and DBH play an essential role for maintaining the transformational
homeostasis and normal functions of the noradrenergic system. Therefore, the modulation of
glucocorticoids on the noradrenergic system may be mediated by affecting the expression of
these two phenotypes.
In a previous study, we found that chronic social defeat (CSD) significantly increased
mRNA and protein levels of the NET in the locus coeruleus (LC), hippocampus, frontal
cortex and amygdala. The latter three regions are the projection areas of the LC neurons.
CSD-induced increases in NET expression were abolished by adrenalectomy or treatment
with corticosteroid receptor antagonists, suggesting the involvement of corticosterone
(CORT) and corticosteroid receptors in this upregulation (Chen et al. 2012). Further, CSD
also increased the expression of DBH in the same brain regions (Fan et al. 2013). In order to
further verify that CORT secreted during stressful events accounts for this effect, adult
Fischer 344 rats were treated with a dose relevant to stress-induced plasma CORT
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concentration, and the expression of NET and DBH in the LC as well as the main NE
terminal regions were examined. Meanwhile, two behavioral tasks, elevated T-maze and
open-field, were performed to examine whether there is a parallel behavioral change after
CORT treatment. The present findings demonstrate that chronic treatment with CORT
upregulated expression of NET and DBH in the LC and its terminal regions, which was
mediated through corticosteroid receptors. The expressional alteration of NET and DBH
induced by CORT was accompanied by increased stressful behavior. These results are
similar to those observed in the CSD model, and indicated that there is an integrative
interaction between chronic stress, through CORT, and the noradrenergic system.

Material and methods
Animals
Male Fischer 344 rats, weighing 200-250g at the beginning of the experiment, were
purchased from Harlan Laboratories Inc. (Indianapolis, IN, USA). All animal procedures
were approved by the Animal Care and Use Committee of East Tennessee State University,
and complied with the NIH Guide for the Care and Use of Laboratory Animals. Rats were
maintained on a 12-h light/dark cycle (lights on at 07:00 am) with ad-libitum access to food
and tap water except as specifically described below. After an acclimation period of 5 days,
rats were randomly assigned to experimental groups.

NIH-PA Author Manuscript

Oral administration with CORT

NIH-PA Author Manuscript

Animal chow was available ad libitum, but drinking water was replaced with a solution
containing 100 μg/ml CORT (Sigma, St. Louis, MO) at 9:00 am of each day for 21 days,
which was freshly prepared daily. Selection of such concentration of CORT was based on
past works, which resulted in an increased plasma CORT level approaching stress induced
levels in animals (Karatsoreos et al. 2010, Donner et al. 2012). Because of its hydrophobic
characteristics, CORT was first dissolved in 100% ethanol, and then diluted in regular tap
water to a final ethanol concentration of 2.4% ethanol. Control rats were given a 2.4%
ethanol solution alone. This vehicle containing 2.4% ethanol itself neither activated the
hypothalamic-pituitary-adrenal axis, nor affected other measurements including organ
weight (adrenal, spleen and thymus), as well as neuronal measurements (Magarinos et al.
1998, Nacher et al. 2004a, Nacher et al. 2004b, Gourley et al. 2009). Some groups of rats
were injected daily with mifepristone (10 mg/kg, daily, s.c.) or spironolactone (15 mg/kg,
daily, s.c.); either alone or in combination around the similar time (9:00 am) as the
replacement of CORT drinking solution daily. Also, a separate set of rats (N=6) was injected
daily with either mifepristone or spironolactone without CORT ingestion. All these
compounds were purchased from Sigma-Aldrich (St. Louis, MO, USA). The doses of these
antagonists were chosen on the basis of previous reports (Ratka et al. 1989, Ni et al. 1995,
Haller et al. 1998, Macunluoglu et al. 2008) and preliminary pilot data. Rats in the untreated
control and CORT alone groups were injected with vehicle. After 3-weeks of exposure to
CORT animals were sacrificed on the 22nd day by rapid decapitation and trunk blood was
collected for measurement of plasma CORT (around 9:30 am). After rats were sacrificed,
brains were removed and rapidly frozen in 2-methyl-butane on dry-ice, then stored at −80°
C until dissection. Trunk blood from rats was quickly collected and prepared for plasma
CORT measurement with the protocol described previously (Chen et al., 2012).
Sucrose consumption test and plasma CORT determination
The methods for these two tests are the same as described before (Chen et al. 2012). Briefly,
the sucrose consumption test was during a one hour window between 06:30 pm and 07:30
pm using a two bottle test (either 1% sucrose solution or tap water). This test was carried out
weekly on the same day of the week (Thursday) throughout the three week CORT ingestion.
J Neurochem. Author manuscript; available in PMC 2015 February 01.
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Sucrose consumption is often used as a measurement of anhedonia in animal models of
stress (Willner et al. 1987, Papp et al. 1991). Plasma CORT was later measured by a
radioimmunoassay using a commercial kit according to the manufacturer’s instructions
[ImmuChem radioimmunoassay kit, MP Biomedicals, LLC in Orangeburg, NY (formerly
ICN Pharmaceuticals, Costa Mesa, CA)].
In situ hybridization
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The in situ hybridization method is the same as described previously (Zhu et al. 2002).
Briefly, slides, where brain sections (16 μm) around the brain stem LC region were mounted
on, were fixed with 4% (w/v) paraformaldehyde followed by acetylation with acetic
anhydride. Lipids were extracted by washing with increasing concentrations of alcohol (50,
70, 95 and 100% [vols]). The [35S]-labeled cRNA probes (Perkinelmer, MA) were
transcribed in vitro from cDNAs for rat NET or DBH in pGEM-3Zf vectors with T7 RNA
polymerase. After incubation with hybridization solution containing the radiolabeled probes
at 55°C for 3-5 hours, sections were then washed extensively and apposed to Biomax
autoradiographic films (Kodak; Rochester, NY). For higher-resolution analyses, sections
were also dipped in Kodak NTB2 emulsion (Fisher, Pittsburgh, PA) and quantitatively
analyzed with the Bioquant Nova program (R.M. Biometrics, Inc.; Nashville, TN). The
specificity of cRNA probes was tested using three criteria. First, sense probes synthesized
from each cDNA were used to perform in situ hybridization in parallel with antisense
probes. There were no specific signals on these slides. Second, antisense probes were used
on control slides from the cerebellum and cortex and no hybridization signals were detected.
Third, antisense probes were hybridized to slides that were treated with RNase A (20 μg/
mL) and no hybridization signal was detected (data not shown).
Detection of protein levels

NIH-PA Author Manuscript

Western blotting was performed to measure protein levels of NET and DBH in the samples
in a similar manner as previously reported (Chen et al., 2012). Briefly, samples were
microdissected or micropunched from rat hippocampus, frontal cortex and amygdala, and
processed by homogenization and centrifugation. Protein concentrations were measured.
Equal amounts of samples (30 μg of protein per lane) were loaded on 10% SDSpolyacrylamide gels for electrophoresis. Protein bands in gels were transferred to
polyvinylidene diflouride membranes by electro-blotting. The membranes were in turn
incubated with a polyclonal primary antibody against NET from rabbit (1:330 dilution;
Alpha Diagnostic Intl. Inc, San Antonio, TX) or DBH from rabbit (1:500 dilution; Santa
Cruz Biotechnology, Inc, Santa Cruz, CA, USA) overnight at 4°C, as well as secondary
antibodies in the next day after washing (horseradish peroxidase-conjugated anti-rabbit IgG,
1:3000; Amersham Biosciences, Little Chalfont, UK). Immunoreactive bands were
visualized by enhanced chemiluminescence (ECL, Amersham; Piscataway, NJ). Bands were
detected by G:Box Imaging (Fyederick, MD, USA), or exposed on films and scanned by
Quantity One imaging devices (Bio-Rad, Hercules, CA). Band densities were then
quantified by imaging software (Molecular Dynamics IQ solutions, Molecular Dynamics,
Inc., Sunnyvale, CA). Before the experiment, the antibody specificity was tested by using
blocking peptides and results showed there was no band at the known molecular weight for
the target after addition of the blocking peptide. Also, a linear standard curve was created
from optical densities (ODs) of bands with a dilution series of total proteins prepared from
brain tissues. OD values of NET or DBH were compared with those of the standard curve to
ensure that detection was in the linear range of measurement. The quantitated value
normalized with β-actin immunoreactivities, which were determined on the same blot, to
assess equal protein loading. Normalized values were then averaged for all replicated gels
and used to calculate the relative changes of the same gel.
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Immunofluorescence staining with NET and DBH
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Rats were transcardially perfused under anesthesia with pentobarbital (40 mg/kg, i.p.) using
4% paraformaldehyde in 0.1 mol/L phosphate buffer, pH 7.4. Brains were stored in 10%
sucrose followed by 30% sucrose and then sectioned at 30 μm using a sliding microtome.
Immunofluorescence staining was performed using commercial polyclonal antibody from
rabbit against NET (Alpha Diagnostic Intl. Inc, San Antonio, TX) or DBH (Protos Biotech
Corp., New York, NY, USA). After washing in phosphate-buffered saline (PBS) and
preincubated in 5% bovine serum albumin in PBS supplemented with 0.2% Triton-X 100 for
1 h at room temperature, brain sections were incubated in primary antibodies (for NET:
1:330 dilution; for DBH: 1:500 dilution, in PBS containing 0.2% Triton-X 100) overnight at
4°C, followed by incubation with secondary antibodies (Alexa Fluor 488-conjugated goat
anti-rabbit IgG, from Invitrogen, Carlsbad, CA, USA) for 2 h at room temperature, which
was subsequently followed by four rinses with 0.1M PBS. Slides were then coverslipped
using Citifluor mounting medium. In order to reduce inter-animal staining variability, each
immunofluorescence stain was performed on all tissue sections at the same time by an
investigator blinded to conditions. Immunofluorescence labeling of NET and DBH was
identified under a Leica TCS SP2 confocal microscope system (Leica Microsystems Inc.,
Bannockburn, IL, USA). Specimens were scanned sequentially to avoid crosstalk between
fluorochromes, and a maximum LC image was obtained from each series. These digital
images were taken with identical exposure times to allow the comparison of fluorescence
intensity between images. Under matched imaging conditions, the negative control showed
no visible staining (see below). Images were then semiquantitatively analyzed by using
ImageJ software (Rasband, US National Institutes of Health, Bethesda, http://
rsbweb.nih.gov/ij, 2010). Reference background levels were obtained from nonimmunoreactive portions of brain sections adjacent to the LC region by determining the
optical density on a 0–255 grayscale (0 being white and 255 black). The area fraction of
immunofluorescence was quantified at three levels of each section and two sections from
each rat. To validate the specificity of these polyclonal antibodies, some slides were
processed to determine the specificity of this immunostaining by 1) using blocking peptides
in which the antibody with the blocking peptide was incubated, and 2) negative control
testing in which the primary antibody was not applied. In both tests, no positive
immunostaining was found in these slides (data not shown).
Behavior tests to measure explorative and anxiety-related behavior
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Two behavioral tests were performed during the last two days of CORT administration
paradigm (21st and 22nd day): the elevated T-maze task and open-field. The order in which
the tasks were performed was balanced across subjects. The elevated T-maze is a modified
version of the more commonly used elevated plus maze, except the maze itself has only
three arms, with the stem of the T-maze enclosed by Plexiglas lateral walls (40 cm high) that
was perpendicular to two open arms. A total of four trials were given: a single baseline trial,
followed by two avoidance trials, subsequently followed by an escape trial following the
protocol of Trivedi and Coover (Trivedi et al. 2004). On the baseline and avoidance trials,
the animal is placed at the end of the stem, and time is recorded as to the latency for the
animal to visit the open arms. On the escape trial, the animal is placed at the end of one of
the two open arms (balanced across subjects) and time is recorded for the animal to visit the
walled arm.
For the open-field task, animals were placed into a square locomotor arena measuring 40 cm
on a side, and all trials lasted for 10 min each. Activity was measured through AnyMaze
software (Stoelting, Wood Dale, IL). This software allows for the analysis of several
dependent measures. For this experiment, locomotor activity, clockwise and
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counterclockwise turning, as well time spent in immobile were measured. In addition,
measurement includes visits to and time spent in a defined central zone in the arena.
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Statistics
All experimental data are presented in the text and graphs as the mean ± SEM. The unpaired
Student’s t-test was used to analyze data of plasma CORT measurement in the experiment of
CORT administration (Fig. 1A). The repeated measures analysis of variance (ANOVA) was
used for the data in Fig. 1B and behavioral tests. For all other analysis, an one-way ANOVA
was used, followed by post hoc Newman-Keuls tests for pairwise comparisons (p<0.05).

Results
Plasma CORT measurement and sucrose consumption test

NIH-PA Author Manuscript

To define the efficacy of CORT administration in inducing hormonal alteration, plasma
CORT levels were measured in collected samples. As shown in Fig. 1A, CORT ingestion
significantly increased plasma CORT levels (p<0.01). Also, the sucrose consumption test
was performed to evaluate depressive effects of CORT ingestion in rats. As shown in Fig.
1B, the intake of the sucrose solution was not significantly changed in untreated animals
over the whole duration of the experiment (p>0.05). However, it was significantly reduced
in the first and second week of CORT treatment (F3,31=7.54, p<0.01). Although the sucrose
consumption in the third week of CORT ingestion also showed a reduced level, it did not
reach statistical significant level when compared to the baseline (0). Nevertheless, it was still
significantly lower when compared to that at the 3rd week time point of the non-treated
animals (P<0.05).
CORT ingestion increases mRNA and protein levels of NET and DBH in the rat LC
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To investigate the influence of CORT ingestion on the expression of NET and DBH in the
LC of rats, as well as whether this influence was mediated by corticosteroid receptors, ex
vivo in situ hybridization was performed to measure mRNA levels of NET and DBH. First,
to examine whether these antagonists alone affected the expression of the noradrenergic
phenotypes, a separate set of rats were injected with vehicle (the control), mifepristone or
spironolactone in the absence of CORT ingestion. As showed in Figs. 2A and 3A, compared
to the mRNA level of NET and DBH in the LC of the control rats, injection of mifepristone
or spironolactone alone did not produce any significant alteration of NET (F2,17 = 0.48,
p>0.05) or DBH (F2,17 = 0.53, p>0.05) mRNA levels. It indicates that without stress
hormones’ binding, glucocorticoid and mineralocorticoid receptors are not activated and
their antagonistic functions are not supposed to be working. In contrast, CORT ingestion
significantly affected mRNA levels of these noradrenergic phenotypes (F4,27 = 3.06, p<0.05
for NET; F4,34 = 3.45, p<0.05 for DBH). Post hoc tests revealed that CORT treatment
increased mRNA levels of NET or DBH in the LC region, respectively, by 281.5% or
163.6% (P<0.05), compared to controls. Furthermore, mifepristone and spironolactone,
alone or in combination, were treated to these CORT-ingested rats. The analysis showed that
treatment with glucocorticoid receptor antagonist mifepristone, or combination of the two
antagonists blocked CORT-induced elevation of NET mRNA levels (p<0.05, respectively,
Fig. 2B). In contrast, CORT-induced increase of DBH mRNA levels in the LC was
completely abolished only by the treatment with combination of mifepristone and
spironolactone (Fig. 3B, p<0.05).
Alteration of NET/DBH protein levels in the LC caused by CORT ingestion was also
examined by inmmunofluorescence staining. The separate experiment to examine effects of
mifepristone or spironolactone on protein levels of NET and DBH in the absence of CORT
demonstrated these antagonists alone did not result in any significant alteration on
J Neurochem. Author manuscript; available in PMC 2015 February 01.
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immunoreactive activities of NET and DBH in the LC (Figs. 4A and 5A; F2,16 = 0.33,
p>0.05 for NET; F2,17 = 0.41, p>0.05 for DBH). However, CORT ingestion markedly
influenced immunoreactive levels of these two phenotypes (F4,44 = 8.37, p<0.01 for NET;
F4,34 = 4.07, p<0.01, for DBH). Further examination revealed that CORT ingestion
significantly increased protein levels of NET and DBH about 74.4% and 71.7%, (both
p<0.01) respectively, compared to those of the control (Figs. 4 and 5). These increased
protein levels were also attenuated by administration of mifepristone alone (P<0.05 for both
NET and DBH), or combination of mifepristone and spironolactone (p<0.05 only for DBH).
CORT ingestion increases protein levels of NET and DBH in the hippocampus, frontal
cortex and amygdala
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Western blotting was performed on samples from the hippocampus, frontal cortex and
amygdala to explore whether CORT ingestion alters NET/DBH protein levels in these
terminal areas of the LC. Treatment of rats with mifepristone or spironolactone in the
absence of CORT did not cause significant changes in protein levels of NET or DBH in
these areas (Table 1). As shown in Fig. 6, CORT ingestion significantly affected NET
protein levels in these terminal regions (F4,39=3.26, p<0.05 for the hippocampus;
F4,39=4.06, p<0.01 for the frontal cortex; F4,34=8.97, p<0.001 for the amygdala). However,
while CORT ingestion similarly changed DBH protein level in the hippocampus
(F4,39=3.01, p<0.05) and amygdala (F4,39=3.16, p<0.05), there was no significant alteration
for DBH protein levels in the samples from the frontal cortex (F4,39=1.01, p>0.05). The
posteriori Newman-Keuls test revealed that the CORT-induced increase of protein levels of
NET (in all three regions) or DBH (in the hippocampus and amygdala) was abolished by
treatment with combination of mifepristone and spironolactone.
CORT ingestion resulted in behavioral changes
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Two behavioral tasks were used to analyze CORT treatments: the elevated T-maze and
open-field. In order to gain insight whether corticosteroid receptor antagonists alone resulted
in any behavioral alteration, a separate experiment was carried out, in which rats were
injected with mifepristone (10 mg/kg, daily, s.c.) or spironolactone (15 mg/kg, daily, s.c.) in
the absence of CORT ingestion for 21 days and the control rats were injected with the
vehicle. The elevated T-maze task showed that either mifepristone or spironolactone
significantly increased Avoidance T1 (F2,15 = 8.52, p<0.004) and Avoidance T2 (F2,15 =
5.63, p<0.01) (60.00 is the maximal value for such test), while leaving the escape trial
unchanged (Table 2). A longer latency to explore the open arms in these groups treated with
antagonists alone represent an increased fear, indicating that these antagonists alone may
have anxiogenic effects. Nevertheless, the open-field tests showed that there was not any
significant alteration after treatment with either mifepristone or spironolactone in the
absence of CORT ingestion (Table 2).
As the biochemical measurements above showed that elevated NET and DBH expression in
most of the brain areas was abolished by simultaneous treatment with combination of
corticosteroid receptor antagonist mifepristone and spironolactone, we only examined
effects of the cocktails (combination of mifepristone and spironolactone, which were daily
injected for 21 days) in the behavior tests for the CORT-involved experiment (Table 3). The
order of these tasks was counterbalanced across subjects, and each task was completed
within a single day. A 2 × 5 repeated measures ANOVA of the avoidance trials on the
elevated T-maze revealed a significant main effect of group (F2,23 = 4.25, p<0.01) and trial
(F2,23 = 6.96, p<0.01). There was no significant effect on analysis of the escape trial.
Controls had a shorter latency to explore the open arms compared to all other groups,
presumably due to a lack of learned fear of the open arms, whereas fear of the open arms
appears to be enhanced in CORT treated subjects, as would be expected, indicating an
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anxiogenic effect caused by CORT. Interestingly, the result of the group of cocktails plus
CORT was not significantly different from that of the CORT group, indicating that a
combination of these antagonists failed to block the avoidance response in CORT treated
subjects. For the open-field task, significant group differences were revealed on horizontal
activity (F2,23 = 5.80, p<0.01) and the number of visits made to a central zone in the arena
(F2,23 = 4.56, p<0.05). In terms of horizontal activity, animals administered with the
antagonists demonstrated a significant increase in horizontal activity compared to the
CORT-treated group and controls. Analysis of visits to the central zone revealed that the
CORT-treated group made less visits to the central zone than the control. This result appears
to indicate that combination of antagonists was effective in blocking CORT-related
behaviors in the open-field. Note that this effect cannot be accounted for by horizontal
activity, because the CORT group was equivalent to the controls on the horizontal activity
measure. Thus, it appears that CORT ingestion induced anxiety as indicated by both of these
tasks. However, the effects of the antagonists were task dependent, in that they were only
effective in blocking effects of CORT on visits to the center zone in the open- field.

Discussion
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Our previous study demonstrated that chronic social defeat in rats up-regulated the
expression of the noradrenergic phenotype in the LC and its terminal regions (Chen et al.
2012). In the present study, we attempted to mimic the stress state through chronic
administration of CORT to rats. Results showed that CORT ingestion significantly increased
both mRNA and protein levels of NET/DBH in the rat LC. The same treatment also
increased NET protein levels in LC projection regions such as the hippocampus, frontal
cortex, and amygdala, as well as DBH protein levels in the hippocampus and amygdala.
Elevated NET and DBH expression in most of these areas (except for NET protein levels in
the LC) was abolished by treatment with combination of corticosteroid receptor antagonist
mifepristone and spironolactone. Also, treatment with mifepristone alone prevented CORTinduced increases of NET expression and DBH protein levels in the LC. Furthermore, this
CORT-induced expressional upregulation of the noradrenergic phenotypes was
accompanied by specific anxiety-like behavioral alterations, as demonstrated by inhibitory
avoidance of the open arm and reduced center zone entries. Taken together, these studies
confirmed that there is a functional linkage between chronic stress and the noradrenergic
system through action of CORT on the expression of noradrenergic phenotypes.
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Dysregulation in the function of the HPA axis activity and central noradrenergic system is a
common feature of many stress-related mental disorders including major depression and
anxiety disorders (Bunney et al. 1965, Thomson et al. 2008). Animal studies have
demonstrated that stress-induced activation of the LC-NE system (Abercrombie & Jacobs
1987) alters the release and metabolism of NE in the noradrenergic neuronal cell bodies and
their terminal regions (Pacak et al. 1995, Smagin et al. 1997). However, whether an
abnormal HPA axis, represented by hypercortisolemia, and a disturbed noradrenergic system
has a causative relationship is not completely clear. Our previous studies demonstrated that
chronic stress increased expression of NET (Chen et al. 2012) and DBH (Fan et al. 2013) in
the LC and its main projection regions, indicating that chronic stress activated the
noradrenergic system by action on noradrenergic phenotypes. To further clarify this
relationship, the present study was carried out through oral administration of CORT to
mimic the chronic stress. Results revealed that CORT ingestion upregulated NET and DBH
expression in most central noradrenergic neurons (except for DBH protein levels in the
frontal cortex, discussed below). The results not only confirmed the similarity between the
CORT ingestion and the CSD models, but also lead us to postulate that elevated NET
(increased reuptake of intracellular NE) and DBH (increase NE synthesis to compensate the
stress-induced release of NE) induced by CORT ingestion may be a necessary response for
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integrating homeostasis, an important adaptive modification of the central NE system
reacted to chronic stress (Goddard et al. 2010). It may be worth mentioning that tyrosine
hydroxylase as a rate-limiting enzyme plays an important role for the biosynthesis of NE.
However, DBH also is a key factor to determine the rate of NE synthesis (Kobayashi et al.
1994, Kim et al. 2002), as disruption of the DBH gene has been reported to block the
synthesis of NE (Sabban 2007, Kvetnansky et al. 2008). The present study demonstrated
that CORT ingestion markedly increased mRNA and protein levels of DBH in the LC, and
DBH protein levels in the hippocampus, and amygdala. These results indicate that in
response to CORT exposure, upregulated expression of DBH in the LC and some terminal
regions may increase synthesis of NE. However, as NE concentration in the brain has not
been measured in the present study, this notion has to be verified by further experiments.
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Stressful life events are potent factors that trigger, induce or exacerbate episodes of
depression. During chronic stress, several hormones and systems are involved. Stressinduced release of glucocorticoids, as the final effector of the HPA axis, and subsequent
activation of corticosteroid receptors in the brain play a crucial role in mounting the adaptive
response to stress. Development of a model that produces a persistent, varied behavioral
alteration would be a major advance for understanding the neurobiology of depression. To
extend our previous work using CSD animal models, non-invasive CORT ingestion was
performed to verify the previous observation. The results showed that oral administration of
100 μg/ml CORT for 3 weeks resulted in a blood concentration of CORT about 56 μg/dl, a
level corresponding to the stress status found in animal studies (Sapolsky et al. 1995). Also,
sucrose consumption, an analog of “anhedonia-like” symptoms in stress paradigm, exhibited
a very similar pattern to that in stress model rats (Chen et al. 2012), indicating that chronic
non-invasive administration of CORT can mimic the CSD model to induce “anhedonia-like”
depressive-like behavior. It is worth pointing out that while reduced sucrose consumption in
the third week of CORT treatment was absolutely lower than that in the controls (p<0.05), it
did not reach the statistical significance when compared to the baseline before the treatment.
Nevertheless, sucrose consumption in the chronic social defeat rat model showed a
consistently decreased state throughout CSD (Chen et al. 2012). This discrepancy between
the CORT ingestion and CSD regime may be accounted by the different experimental
paradigm used in these two studies. In the previous study, a paradigm of 4 week stress with
variable defeat session schedules was used for the purpose to avoid the habituation of rats to
a regular schedule. In contrast, in the present study, CORT was administrated daily. A
habituation may occur during this period. The curve of the sucrose consumption can verify
this phenomenon: the lowest sucrose consumption rate appeared in the first week of CORT
ingestion, which seemed to be attenuated with time.
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In the present study, CORT ingestion significantly increased expression of NET in the LC
region and its major terminal regions, as well as the expression of DBH in the most of these
regions. However, no significant changes were found in DBH protein levels in the frontal
cortex after CORT ingestion. In contrast, CSD regimen upregulated DBH protein levels in
all major terminal regions (Fan et al. 2013). Currently we do not have a satisfactory
explanation for this discrepancy of DBH protein levels between the present study and
previous CSD experiment. While the technical factors related to measurement may be
considered, the similar phenomenon has been reported previously. For example, chronic
stress significantly reduced expression of brain-derived neurotrophic factors in the frontal
cortex (Roceri et al. 2004, Mao et al. 2010, Li et al. 2012), whereas chronic administration
of CORT had no significant effect on mRNA and protein levels of the same factor in the
same brain region (Jacobsen et al. 2006). One of the possibilities for such different effect on
DBH expression between chronic stress and CORT treatment may be explained by the fact
that chronic stress is involved by more hormones and signal transduction pathways (Kwon et
al. 2007). Multiple hormones and their activated signal transduction pathways may produce
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relatively stronger effects on the DBH gene, which has several cis- and trans-regulatory
elements in the prompter regions (Shaskus et al. 1992, Afar et al. 1996), than that caused by
CORT treatment alone. In addition, given that DBH expression levels are lower in cortical
regions (Schroeter et al. 2000), the effect from CORT ingestion on DBH in the frontal
cortex may be smaller than other regions, although DBH expression there still shows a
potential enhancement.
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Regarding behavior, the corticosteroid receptor antagonists increased overall horizontal
activity. Although there are no studies to show chronic effects of the combination of these
antagonists on behavioral activity, one study has shown that an acute dose of mifepristone
had no effect on behavioral activity (De Vries et al. 1996). These antagonists have been
shown to alleviate motor impairments caused by stress and CORT treatment, whereas either
antagonist alone produced no significant differences compared to controls (Jadavji et al.
2011). Studies using the immunohistochemical technique have shown the presence of
glucocorticoid receptors in the motor cortex, basal ganglia, and cerebellum (Ahima &
Harlan, 1990; Ahima et al. 1991), thus rendering these motor brain regions sensitive to the
actions of glucocorticoid receptors. By contrast, mineralocorticoid receptors in the motor
system appear to be restricted to cortical areas, but are present in the motor cortex (Roland et
al. 1995). Therefore, blockade of both receptors appears to produce a synergistic effect on
specific behavioral activity in the status of stress or CORT treatment. Regardless, the task
dependent effects of the CORT antagonist cocktail emphasizes that these tasks measure
different types of behaviors related to stressful events, but also highlight the complexity of
behavioral testing. A recent review (Ramos 2008) nicely summarizes and emphasizes the
importance of different behavioral tasks related to emotionality, anxiety, and stress to
provide a comprehensive profile of the effects of stress on behavior.
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CORT appears to have increased anxiety as measured on the elevated T-maze, which was
not alleviated by the corticosteroid receptor antagonist cocktail. This may be due to the fact
that the cocktail was given only once daily, but oral administration of CORT was continuing
throughout the day over the entire three-week period. Thus, the antagonist cocktail did not
sufficiently block the effects of CORT on anxiety as tested on the elevated T-maze. It was
noteworthy that elevated T-maze tasks showed that either mifepristone or spironolactone in
the absence of CORT ingestion resulted in a significant increase in Avoidance tests (Table
2), indicating that these antagonists alone may have potential anxiogenic effects. Although
these results may explain the reason why the cocktail failed to reverse CORT-induced
anxiety-like behavior (Table 3), they are in conflict to the available reports in the literature.
It was reported that treatment with spironolactone or other MR antagonists, either by
infusion into the brain or systematic administration, exerted anxiolytic effect, but not for GR
antagonists (Korte et al. 1995, Smythe et al. 1997, Bitran et al. 1998, Hlavacova et al.
2010). Other studies also showed that treatment with mifepristone had no any anxiogenic
effects (Calfa et al. 2006, Auger et al. 2008). Currently, we do not have a satisfactory
explanation for such conflict. Different species of rats (Fischer 344 in the present study
verse Wistar or others in those reports) may account for these differences, as it is well
established that individual rats exhibit marked differences in behavioral responses to a novel
environment (Kabbaj et al. 2000). Also, another attributable factor for such conflict may be
the difference in the treatment period: 21 days in the present study verse 3 to 11 days in
those reports. Since biochemical measurements in the current study showed that these
antagonist administered alone did not cause a significant alteration for expression of NET
and DBH in the absence of CORT, these potential anxiogenic effects may not be related to
these phenotypes in the brain. As the study to use antagonists alone to test their behavioral
effects is limited, further studies are warranted to pursue this issue.
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The reason of possible non-involvement of noradrenergic phenotypes in these antagonistsinduced anxiogenic effects is not known, as even the degree that noradrenergic systems
modulate behavioral state remained ambiguous. The LC-NE system is a critical component
of the neural architecture. As such, it appears reasonable to propose that dysregulation of
this system might contribute to dysregulation of a variety of cognitive and affective
processes, resulting in specific behavioral alteration such as anxiety. However, the data in
the literature show some difference. For example, rats with 6-OHDA-induced LC ablation
did not show any signs of impairment in learning and performance of feat-motivated tasks
(Mason et al. 1979). Also, noradrenaline depleted rats were more reluctant to leave a
familiar place and took longer to consume the food pellets in an unfamiliar place, suggesting
an increase in fear following the lesion. Moreover, there was no difference in the behavioral
parameters (elevated plus-maze, light-dark box and open-field test) between DBH (−/−) and
DBH (+/−) mice (Cryan et al. 2001, Marino et al. 2005). Therefore, while we think the
alteration of CORT-induced noradrenergic phenotype alterations possibly account for the
specific behavioral changes in the present study, there is another notion that the LC-NE
system may be viewed as a general and global modulator of neuronal circuits that guide
behavioral action (Itoi 2008, Itoi et al. 2010).
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In summary, the present study demonstrates that non-invasive CORT administration
significantly upregulated NET and DBH expression in the LC and its main terminal regions
and it was mediated by corticosteroid receptors, a similar phenomenon to that of CSD
regime as reported previously (Chen et al. 2012). In addition, the CORT ingestion not only
induced anhedonia-like behavior, but also anxiety behavioral alteration. Taken together with
previous observations, the results of the present study indicate that CORT plays a primary
role in the chronic stress-induced activates the LC-NE system, which may be related to the
pathophysiology of stress-precipitated psychiatric disorders.
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Figure 1.

Effects of CORT ingestion (n=8/group) on plasma CORT concentrations (A) and sucrose
consumption (B). * p<0.05, ** p<0.01, compared to the control (A) or corresponding time
point in the control group (B); † p<0.05, †† p<0.01, compared to the baseline of sucrose
consumption (0 week).
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Figure 2.

Effects of corticosteroid receptor antagonists alone (A, n=6/group), CORT ingestion, and
CORT ingestion plus treatment with corticosteroid receptor antagonists (B, n=8/group) on
NET mRNA in the LC. Upper panel in A and B: NET mRNA in LC tissues of rats detected
by in situ hybridization. Coronal brain sections were taken at 9.7 mm posterior from bregma
(corresponding to Plate 58 in the brain atlas) (Paxinos et al. 2005). Lower panel in A and B:
Quantitative analyses of mRNA in slides. * p<0.05, compared to the control; † p<0.05,
compared to the CORT ingestion group. Con: control; CSDM: CORT plus treatment with
mifepristone; CSDS: CORT plus treatment with spironolactone; CSDMS: CORT plus
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treatment with both mifepristone and spironolactone; Mife: mifepristone; Spiro:
spironolactone. Scale bar: 50 μm for all images.
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Figure 3.

Effects of corticosteroid receptor antagonists alone (A, n=6/group), CORT ingestion, and
CORT ingestion plus treatment with corticosteroid receptor antagonists (B, n=8/group) on
DBH mRNA levels in the LC. Upper panel in A and B: DBH mRNA in the LC detected by
in situ hybridization. Lower panel in A and B: quantitative analysis of DBH mRNA obtained
in slides, * P<0.05, compared to the control, † P<0.05, compared to the CORT ingestion
group. See Fig. 2 for abbreviations. Scale bar: 50 μm for all images.
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Figure 4.

Effects of corticosteroid receptor antagonists alone (A, n=6/group), CORT ingestion, and
CORT ingestion plus treatment with corticosteroid receptor antagonists (B, n=6/group) on
NET-immunoreactivity in the LC. The top panels in A and B are representative micrographs
of NET immunofluorescence in the LC region from experimental rats. The bottom panels in
A and B show measurements of the area fraction of NET immunofluorescence in the LC
region. * P<0.05, compared to the control; † P<0.05, compared to the CORT ingestion
group. See Fig. 2 for abbreviations. Scale bar: 50 μm for all images.
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Figure 5.

Effects of corticosteroid receptor antagonists alone (A, n=6/group), CORT ingestion, and
CORT ingestion plus treatment with corticosteroid receptor antagonists (B, n=6/group) on
DBH-immunoreactivity in the LC. The top panels are representative micrographs of DBH
immunofluorescence in the LC region from experimental rats. The bottom panels show
measurements of the area fraction of DBH immunofluorescence in the LC region. * P<0.05,
compared to the control; † P<0.05, compared to the CORT ingestion group. See Fig. 2 for
abbreviations. Scale bar: 50 μm for all images.
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Figure 6.

Effect of CORT ingestion, and CORT ingestion plus treatment with corticosteroid receptor
antagonists on NET protein levels in the LC terminal regions. The upper left panel is the
neuroanatomical figure to depict the microdissection/micropunch regions used for western
blotting. The upper right figures show autoradiographs obtained by western blotting of NET
in the hippocampus (HP), frontal cortex (FC) and amygdala (Amy) (n=6-8/group). The
lower graph shows quantitative analysis of band densities. Values of NET bands were
normalized to those of β-actin probed on the same blot. *P<0.05, compared to the control
group; † p<0.05, compared to the CORT group. See Fig. 2 for abbreviations.
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Figure 7.

Effect of CORT ingestion, and CORT ingestion plus treatment with corticosteroid receptor
antagonists on DBH protein levels in the LC terminal regions. The upper figures show
autoradiographs obtained by western blotting of NET in the hippocampus (HP), and
amygdala (Amy) (n=6-8/group). The lower graph shows quantitative analysis of band
densities. Values of NET bands were normalized to those of β-actin probed on the same blot.
*P<0.05, compared to the control group; † p<0.05, compared to the CORT group. See Fig.
2 for abbreviations.
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Effects of corticosteroid receptor antagonists on protein levels of NET and DBH in the hippocampus (Hipp),
frontal cortex (FC) and amygdala (Amy) in the absence of CORT
Group

NET

DBH

Hipp

FC

Amy

Hipp

FC

Amy

Control
(n=6)

0.318± 0.01

0.347±0.02

0.179±0.02

0.555±0.01

0.486±0.06

0.183±0.03

Mifepristone
(n=6)

0.326± 0.07

0.352±0.01

0.187±0.06

0.503± 0.03

0.472±0.04

0.192±0.04

Spironolactone
(n=6)

0.306± 0.09

0.349±0.02

0.173±0.03

0.548± 0.07

0.497±0.03

0.176±0.05

Value donated are means±SE and are expressed as the relative abundance of proteins which were normalized by the value of ß-actin. There is no
statistical significant difference among the groups.
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Behavior tests for mifepristone and spironolactone in the absence of CORT as measured by elevated t-maze
(top) and open-field (bottom)
Mean
Avoidance
T2(s)

Mean Escape
Trial (s)

N

Group

Mean
Avoidance
T1(s)

Control

35.67 ± 8.76

44.253 ± 9.86

37.69 ± 11.90

6

Mifepristone

60.00*†

60.00*

32.20 ±11.20

5

Spironolactone

60.00*

60.00*

44.00 ± 3.64

5

Group

Horizontal
Activity Counts

Center Zone
Entries

N

Control

552.33 ± 41.63

28.17 ± 2.78

6

Mifepristone

479.00 ± 39.90

33.40 ± 2.33

5

Spironolactone

466.20 ± 47.10

37.50 ± 10.17

5

N: the number of rats in each group.
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*

p<0.05, , compared to the control.

†

There are no standard errors. 60 was the maximal value for each trial.
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Behavior tests for CORT and CORT plus mifepristone and spironolactone (Antagonists) as measured by
elevated T-maze (top) and open-field (bottom).

Group

Mean
Avoidance
T1(s)

Mean
Avoidance
T2 (s)

Mean Escape
Trial (s)

N

Control

26.78 ± 9.20

38.33 ± 7.90

40.00 ± 6.50

8

CORT

40.11 ± 8.00*

58.30 ± 1.70*

41.20 ± 6.10

9

CORT
Antagonists

41.38 ± 8.60*

58.50 ± 1.50*

50.71 ± 5.96

9

Group

Horizontal
Activity Counts

Center Zone
Entries

N

Control

627.00 ± 46.70

33.67 ± 3.40

8

CORT

617.00 ± 97.50

12.50 ± 3.40*

9

CORT
Antagonists

959.30 ± 76.70*†

32.30 ± 3.39†

9
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N: the number of rats in each group.
*

p<0.05, compared to the control.

†

p<0.05, compared to the CORT group.
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